No Data
Heavy Pharmaceuticals Holdings: 2024 Annual Results Forecast
C.Q. Pharmaceutical Holding (000950.SZ) issued a profit warning, expecting net income between 0.29 billion yuan and 0.39 billion yuan, a year-on-year decline of 40.45% to 55.72%.
C.Q. Pharmaceutical Holding (000950.SZ) disclosed its performance forecast for 2024, with the company expecting profits attributable to Shareholders of the listed company...
C.Q. Pharma's Unit Gets Drug Registration Certificate for Mirabegron Tablets
C.Q. Pharmaceutical Holding (000950.SZ): C.Q. Pharmaceutical has received the pharmaceutical registration certificate for Mirabegron extended-release tablets.
On January 9, Gelonghui reported that C.Q. Pharmaceutical Holding (000950.SZ) announced that its subsidiary, Chongqing Pharmaceutical (Group) Co., Ltd. (referred to as "C.Q. Pharmaceutical"), recently received the Pharmaceutical registration certificate for Mirabegron Sustained-release Tablets approved by the National Medical Products Administration. Mirabegron Sustained-release Tablets were developed by Astellas Pharma Europe B.V., first launched in Japan in September 2011 under the trade name Betanis; approved by the FDA in the USA in June 2012, under the trade name Myrbetriq.
Some Investors May Be Worried About C.Q. Pharmaceutical Holding's (SZSE:000950) Returns On Capital
C.Q. Pharmaceutical Holding (000950.SZ): Currently, there are no projects using large models for the development of Innovative Drugs.
Gelonghui reported on December 12 that C.Q. Pharmaceutical Holding (000950.SZ) stated on the investor interaction platform that the company currently has no projects using large models for the development of Innovative Drugs.
The Returns At C.Q. Pharmaceutical Holding (SZSE:000950) Aren't Growing
